LncRNA LINC00924 upregulates NDRG2 to inhibit epithelial-mesenchymal transition via sponging miR-6755-5p in hepatitis B virus-related hepatocellular carcinoma
- PMID: 34997970
- DOI: 10.1002/jmv.27578
LncRNA LINC00924 upregulates NDRG2 to inhibit epithelial-mesenchymal transition via sponging miR-6755-5p in hepatitis B virus-related hepatocellular carcinoma
Erratum in
-
Corrigendum.J Med Virol. 2022 Dec;94(12):6133. doi: 10.1002/jmv.28136. Epub 2022 Sep 19. J Med Virol. 2022. PMID: 36086946 No abstract available.
-
Corrigendum.J Med Virol. 2023 Jan;95(1):e28332. doi: 10.1002/jmv.28332. J Med Virol. 2023. PMID: 36617156 No abstract available.
Abstract
Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is a life-threatening cancer. Long noncoding RNAs participate in HBV-related HCC progression. Based on the bioinformatics analysis, LINC00924 downregulation is positively related to unfavorable outcomes in patients with HBV-related HCC. Herein, we detected the biological functions and regulatory system of LINC00924 in HCC. The LINC00924 downregulation in HBV-related HCC tissues and cells was revealed by reverse transcription-quantitative polymerase chain reaction. Functionally, as Transwell assays and western blotting indicated, LINC00924 elevation inhibited HCC cell invasion and epithelial-mesenchymal transition (EMT). The binding site between LINC00924 and miR-6755-5p was determined by luciferase reporter assays. miR-6755-5p was confirmed to target NDRG2. miR-6755-5p upregulation decreased NDRG2 messenger RNA (mRNA) and protein levels. The mRNA and protein levels of NDRG2 were downregulated in tissues and cells. NDRG2 knockdown attenuated the inhibition induced by LINC00924 overexpression on invasion and EMT of HCC cells. In summary, LINC00924 increases NDRG2 expression to inhibit EMT by targeting miR-6755-5p in HBV-related HCC.
Keywords: HBV-related HCC; LINC00924; NDRG2; epithelial-mesenchymal transition; miR-6755-5p.
© 2022 Wiley Periodicals LLC.
References
REFERENCES
-
- Chen WQ, Li H, Sun KX, et al. [Report of cancer incidence and mortality in China, 2014]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2018;40(1):5-13.
-
- Akinyemiju C, Abera S, Ahmed M, et al, Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA oncology. 2017;3(12):1683-1691.
-
- Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepatitis. 2009;16(7):453-463.
-
- Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84-S101.
-
- Wu Z, Wei C, Wang L, He L. Determining the Traditional Chinese Medicine (TCM) Syndrome with the best prognosis of HBV-related HCC and exploring the related mechanism using network pharmacology. eCAM. 2021;2021:9991533.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical